Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Percentage of Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:

	Net Product Sales						Accounts Receivable
	Three Months Ended September 30, 2024			Nine Months Ended September 30, 2024			As of September 30, 2024
Customer A		43.4	%		44.5	%		41.4	%
Customer B		35.0	%		35.8	%		36.3	%
Customer C		20.2	%		18.5	%		22.0	%
Total		98.6	%		98.8	%		99.7	%

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
CINVANTI net product sales	$	22,662	$	23,270	$	73,205	$	70,599
SUSTOL net product sales		2,763		3,439		10,623		9,258
ZYNRELEF net product sales		6,245		4,372		17,089		12,033
APONVIE net product sales		1,140		353		2,587		921
Total net product sales	$	32,810	$	31,434	$	103,504	$	92,811

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total
Balance at December 31, 2023	$	4,776		$	4,419		$	27,334		$	36,529
Provision		(750	)		21,314			150,281			170,845
Payments/credits		(638	)		(20,261	)		(151,592	)		(172,491	)
Balance at September 30, 2024	$	3,388		$	5,472		$	26,023		$	34,883

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

	September 30,
	2024		2023
Stock options outstanding		26,156		31,317
Restricted stock units outstanding		1,547		1,786
Warrants outstanding		298		298
Shares of common stock underlying convertible notes outstanding		9,819		9,819